ARCOMA Stock Overview
Develops, produces, and provides radiology solutions worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Arcoma AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 10.95 |
| 52 Week High | SEK 18.30 |
| 52 Week Low | SEK 6.30 |
| Beta | 0.88 |
| 11 Month Change | -26.76% |
| 3 Month Change | -26.76% |
| 1 Year Change | 46.98% |
| 33 Year Change | -8.37% |
| 5 Year Change | -51.12% |
| Change since IPO | -20.07% |
Recent News & Updates
Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price Drop
Nov 09
Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business
Aug 22At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?
Aug 07Recent updates
Lacklustre Performance Is Driving Arcoma AB's (STO:ARCOMA) 28% Price Drop
Nov 09Solid Earnings Reflect Arcoma's (STO:ARCOMA) Strength As A Business
Aug 22At kr15.20, Is Arcoma AB (STO:ARCOMA) Worth Looking At Closely?
Aug 07Is Now The Time To Look At Buying Arcoma AB (STO:ARCOMA)?
Apr 26Arcoma AB's (STO:ARCOMA) P/E Is Still On The Mark Following 25% Share Price Bounce
Feb 06Is Arcoma (STO:ARCOMA) A Risky Investment?
Jan 15We Think Arcoma (STO:ARCOMA) Is Taking Some Risk With Its Debt
Sep 11Is Arcoma (STO:ARCOMA) Using Too Much Debt?
Jun 08Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?
Apr 27Does Arcoma (STO:ARCOMA) Have A Healthy Balance Sheet?
Dec 22Is Arcoma (STO:ARCOMA) Using Too Much Debt?
May 03These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Extensively
Oct 28Is Arcoma (STO:ARCOMA) A Risky Investment?
Mar 17Is Arcoma AB (STO:ARCOMA) Potentially Undervalued?
Feb 04Have Insiders Sold Arcoma AB (STO:ARCOMA) Shares Recently?
Jan 14
Arcoma AB's (STO:ARCOMA) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Jan 12These 4 Measures Indicate That Arcoma (STO:ARCOMA) Is Using Debt Reasonably Well
Dec 17Estimating The Fair Value Of Arcoma AB (STO:ARCOMA)
Nov 21Shareholder Returns
| ARCOMA | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 0.5% | -4.1% | -2.1% |
| 1Y | 47.0% | -9.7% | 10.8% |
Return vs Industry: ARCOMA exceeded the Swedish Medical Equipment industry which returned -9.7% over the past year.
Return vs Market: ARCOMA exceeded the Swedish Market which returned 10.8% over the past year.
Price Volatility
| ARCOMA volatility | |
|---|---|
| ARCOMA Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 7.5% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ARCOMA has not had significant price volatility in the past 3 months compared to the Swedish market.
Volatility Over Time: ARCOMA's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 32 | Mattias Leire | www.arcoma.se |
Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray systems for radiographic applications, as well as for use in general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. The company sells its products through OEM partners.
Arcoma AB Fundamentals Summary
| ARCOMA fundamental statistics | |
|---|---|
| Market cap | SEK 144.38m |
| Earnings (TTM) | SEK 12.98m |
| Revenue (TTM) | SEK 171.33m |
11.1x
P/E Ratio0.8x
P/S RatioIs ARCOMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARCOMA income statement (TTM) | |
|---|---|
| Revenue | SEK 171.33m |
| Cost of Revenue | SEK 105.73m |
| Gross Profit | SEK 65.60m |
| Other Expenses | SEK 52.62m |
| Earnings | SEK 12.98m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.98 |
| Gross Margin | 38.29% |
| Net Profit Margin | 7.58% |
| Debt/Equity Ratio | 0% |
How did ARCOMA perform over the long term?
See historical performance and comparison